enVVeno Medical Corporation (NVNO) Key Metrics
NVNO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.2M
- Enterprise value
- −$15.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 216.9
- Price / book
- 0.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.29
NVNO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNVNO returns How much profit the business earns on the capital it uses.
NVNO financial health Debt, liquidity and how easily interest is covered.
NVNO efficiency & capital use Working capital cycle and where the cash goes.
NVNO valuation history
NVNO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NVNO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NVNO price vs earnings per share
NVNO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $6.6M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$20.9M | — | — | — | — | — | — | — | — | — |
| Price / book | 0.2 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −294.3% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −235.3% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $11.23 | $105.70 | $179.90 | $178.50 | $230.65 | $302.75 | $481.25 | $1,290.62 | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$33.06 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$26.43 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$26.44 | — | — | — | — | — | — | — | — | — |
| Cash per share | $47.90 | — | — | — | — | — | — | — | — | — |
| Book value per share | $46.06 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $46.06 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.01 | — | — | — | — | — | — | — | — | — |
| Debt per share | $1.19 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 589K | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −56.2% | −49.4% | −55.4% | −53.0% | −53.7% | −225.9% | −503.9% | — | — | — |
| Return on assets (ROA) | −52.3% | −46.6% | −52.1% | −49.7% | −48.4% | −130.8% | −218.1% | −451.7% | −389.8% | −252.8% |
| Return on tangible assets | −65.9% | −48.5% | −48.4% | −59.2% | −28.6% | −86.7% | −222.0% | −450.8% | −704.8% | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | −998.1% | −482.3% |
| Financial health | ||||||||||
| Total debt | $700,000 | $1.1M | $1.4M | $1.7M | $2.0M | $880,648 | $856,633 | $26,985 | $2.6M | $632,772 |
| Cash & short-term investments | $28.2M | $43.2M | $46.4M | $39.0M | $54.7M | $9.3M | $1.3M | $2.7M | $77,688 | $56,514 |
| Net debt | −$27.5M | −$42.1M | −$45.0M | −$37.3M | −$52.7M | −$8.5M | −$450,598 | −$2.7M | $2.5M | $576,258 |
| Debt / equity | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.12 | 0.87 | 0.01 | — | — |
| Debt / assets | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.08 | 0.25 | 0.01 | 1.18 | 0.35 |
| Current ratio | 13.58 | 20.88 | 34.23 | 25.78 | 34.83 | 3.00 | 0.76 | 1.86 | 0.02 | 0.19 |
| Quick ratio | 13.58 | 20.88 | 34.23 | 25.78 | 34.83 | 3.00 | 0.76 | 1.86 | 0.02 | 0.15 |
| Interest coverage | — | — | — | -94.8 | -902.9 | — | — | -1.1 | -3.2 | -80.5 |
| Working capital | $26.7M | $41.6M | $45.6M | $37.9M | $53.5M | $6.4M | −$452,434 | $1.3M | −$8.0M | −$1.7M |
| Invested capital | −$382,000 | $70,000 | $1.2M | $1.4M | $1.7M | −$1.4M | $539,342 | −$677,217 | −$8.6M | −$3.6M |
| Tangible asset value | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M | $7.1M | $989,940 | $1.4M | −$7.1M | −$1.5M |
| Net current asset value | $26.4M | $40.9M | $44.5M | $36.5M | $51.7M | $6.1M | −$1.0M | $1.3M | −$8.0M | −$1.7M |
| Graham net-net per share | $43.77 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | — | — | — | — | — | — | 1,164.7% | 6.7% | 2.6% | 47.5% |
| Capex / depreciation | 0.01 | 0.07 | 0.06 | 0.22 | 0.81 | 0.47 | 0.92 | 0.09 | 0.08 | 2.47 |
| Stock-based compensation / revenue | — | — | — | — | — | — | 3,015.0% | 1,030.5% | 208.1% | 192.2% |
| R&D / revenue | — | — | — | — | — | — | 7,061.2% | 664.0% | 153.9% | — |
| SG&A / revenue | — | — | — | — | — | — | 15,720.7% | 3,475.1% | 1,292.5% | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | 65.7 | 101.6 | 92.8 |
| Days of inventory on hand | — | — | — | — | — | — | — | — | — | 34.5 |
| Days payables outstanding | 509.1 | 495.3 | 359.3 | 420.0 | 785.9 | 1,241.3 | — | — | 650.9 | 220.2 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | -519.6 | -92.9 |
| Receivables turnover | — | — | — | — | — | — | — | 5.55 | 3.59 | 3.93 |
| Payables turnover | 0.72 | 0.74 | 1.02 | 0.87 | 0.46 | 0.29 | 0.00 | 0.00 | 0.56 | 1.66 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 10.58 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.21 | 0.34 |
| Average receivables | — | — | — | — | — | — | — | $33,602 | $117,466 | $199,750 |
| Average payables | $682,000 | $716,500 | $537,500 | $604,042 | $975,222 | $1.3M | $1.1M | $1.3M | $996,600 | $580,118 |
| Average inventory | — | — | — | — | — | — | — | — | $45,454 | $90,908 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 18.7% | 50.1% | 69.1% |
Computed from NVNO's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NVNO valuation and financial ratios
enVVeno Medical earned a return on equity of −56.2% in fiscal 2025. It ended the year with $0.7 million of debt and $28.2 million in cash and short-term investments, a net cash position of $27.5 million.
See the NVNO income statement, the NVNO chart for price history, or the NVNO stock overview for the latest quote and news.
NVNO key metrics FAQ
What is enVVeno Medical's return on equity?
enVVeno Medical's return on equity (ROE) was −56.2% in fiscal 2025: net income of -$19.5 million on average shareholders' equity of $34.6 million.
How much debt does enVVeno Medical have?
enVVeno Medical had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is enVVeno Medical's free cash flow yield?
enVVeno Medical generated -$15.6 million of free cash flow in fiscal 2025, a free cash flow yield of −235.3% on its market value at year-end ($6.6 million).
What is enVVeno Medical's current ratio?
enVVeno Medical's current ratio was 13.58 at the end of fiscal 2025: current assets were 13.58 times current liabilities.